Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2018 Apr 2

PMID 29605826

Citations 34

Authors

Shushu Wang

Yueyang Liang

Wenxiao Chang

Baoquan Hu

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Triple negative breast cancer (TNBC) has a more aggressive recurrence. Previous reports have demonstrated that sphingosine kinase 1 (SphK1) is a crucial regulator of breast cancer progression. However, the correlation of SphK1 with clinical prognosis has been poorly investigated. Thus, we aimed to elaborate the role of SphK1 in TNBC metastasis. MATERIAL AND METHODS We first determined the level of SphK1 in breast cancer tissue samples and breast cancer cells. Furthermore, the expression of HER2 and phosphor-SphK1 (pSphK1) in human breast cancer tissue samples was determined by immunohistochemical analysis. Associations between SphK1 and clinical parameters of tumors were analyzed. The activity of SphK1 was measured by fluorescence analysis. Extracellular sphingosine-1-phosphate (S1P) was detected using an ELISA kit. Associations between SphK1 and metastasis potential were analyzed by Transwell assay. RESULTS Levels of SphK1 in TNBC patients were significantly higher than levels in other patients with other breast tumors. The expression of SphK1 was positively correlated with poor overall survival (OS) and progression-free survival (PFS), as well as poor response to 5-FU and doxorubicin. The depression of SphK1 thus could repress the Notch signaling pathway, reduce migration, and invasion of TNBC cells in vivo and in vitro. Furthermore, silencing of SphK1 by Ad-SPHK1-siRNA or SphK1 inhibitor PF543 sensitized TNBCs to 5-FU and doxorubicin. Our results also indicated that SphK1 inhibition could effectively counteracts tumors metastasis via Notch signaling pathways, indicating a potentially anti-tumor strategy in TNBC. CONCLUSIONS We found that elevated levels of pSphK1 were positive correlation with high expression of S1P, which in turn promoted metastasis of TNBC through S1P/S1PR3/Notch signaling pathway.

Citing Articles

The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib.

Zhang J, Wang Z, Wei X, Han M, Yan R, Ma L Curr Res Pharmacol Drug Discov. 2025; 8:100212.

PMID: 39896887 PMC: 11787445. DOI: 10.1016/j.crphar.2024.100212.

Elucidation of Dysregulated Pathways Associated With Hypoxia in Oestrogen Receptor-Negative Breast Cancer.

Shamis S, Quinn J, Al-Badran S, McKenzie M, Hatthakarnkul P, Lynch G Cancer Med. 2024; 13(23):e70274.

PMID: 39660488 PMC: 11632397. DOI: 10.1002/cam4.70274.

Lipid profiling of RON and DEK-dependent signaling in breast cancer guides discovery of gene networks predictive of poor outcomes.

Vicente-Munoz S, Davis J, Lane A, Lane A, Waltz S, Wells S Front Oncol. 2024; 14:1382986.

PMID: 39351361 PMC: 11440356. DOI: 10.3389/fonc.2024.1382986.

Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy.

Sukocheva O, Neganova M, Aleksandrova Y, Burcher J, Chugunova E, Fan R Cell Commun Signal. 2024; 22(1):251.

PMID: 38698424 PMC: 11064425. DOI: 10.1186/s12964-024-01626-6.

Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression.

Fedele M, Cerchia L, Battista S Cells. 2024; 13(4.

PMID: 38391963 PMC: 10887430. DOI: 10.3390/cells13040350.

References

Mohammed S, Harikumar K . Sphingosine 1-Phosphate: A Novel Target for Lung Disorders. Front Immunol. 2017; 8:296. PMC: 5348531. DOI: 10.3389/fimmu.2017.00296. View

Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S . Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2007; 112(1):41-52. DOI: 10.1007/s10549-007-9836-9. View

Albinet V, Bats M, Huwiler A, Rochaix P, Chevreau C, Segui B . Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells. Oncogene. 2013; 33(26):3364-73. DOI: 10.1038/onc.2013.303. View

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

Fleisher B, Clarke C, Ait-Oudhia S . Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press). 2016; 8:183-197. PMC: 5063595. DOI: 10.2147/BCTT.S114659. View

Rossmeisl J, Hall-Manning K, Robertson J, King J, Davalos R, Debinski W . Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. Onco Targets Ther. 2017; 10:2077-2085. PMC: 5396930. DOI: 10.2147/OTT.S132964. View

Bernier J, Poortmans P . Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics. Breast. 2016; 28:148-55. DOI: 10.1016/j.breast.2016.05.014. View

Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6:vi7-12. DOI: 10.1093/annonc/mds187. View

Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G . Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist. 2011; 16(9):1215-27. PMC: 3228169. DOI: 10.1634/theoncologist.2011-0098. View

10.

Proia R, Hla T . Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015; 125(4):1379-87. PMC: 4409021. DOI: 10.1172/JCI76369. View

11.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L . Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014; (6):CD006242. PMC: 6464904. DOI: 10.1002/14651858.CD006242.pub2. View

12.

Mao-Draayer Y, Sarazin J, Fox D, Schiopu E . The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol. 2016; 175:10-15. PMC: 5315594. DOI: 10.1016/j.clim.2016.11.008. View

13.

Afghahi A, Telli M, Kurian A . Genetics of triple-negative breast cancer: Implications for patient care. Curr Probl Cancer. 2017; 40(2-4):130-140. DOI: 10.1016/j.currproblcancer.2016.09.007. View

14.

Herold C, Anders C . New targets for triple-negative breast cancer. Oncology (Williston Park). 2013; 27(9):846-54. View

15.

Shukla G, Khera H, Srivastava A, Khare P, Patidar R, Saxena R . Therapeutic Potential, Challenges and Future Perspective of Cancer Stem Cells in Translational Oncology: A Critical Review. Curr Stem Cell Res Ther. 2016; 12(3):207-224. DOI: 10.2174/1574888X11666161028143224. View

16.

Madhunapantula S, Hengst J, Gowda R, Fox T, Yun J, Robertson G . Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012; 25(2):259-74. PMC: 3290340. DOI: 10.1111/j.1755-148X.2012.00970.x. View

17.

Massarotti C, Scaruffi P, Lambertini M, Remorgida V, Del Mastro L, Anserini P . State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. Cancer Treat Rev. 2017; 57:50-57. DOI: 10.1016/j.ctrv.2017.04.009. View

18.

Hubalek M, Czech T, Muller H . Biological Subtypes of Triple-Negative Breast Cancer. Breast Care (Basel). 2017; 12(1):8-14. PMC: 5465739. DOI: 10.1159/000455820. View

19.

Selvam S, De Palma R, Oaks J, Oleinik N, Peterson Y, Stahelin R . Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. Sci Signal. 2015; 8(381):ra58. PMC: 4492107. DOI: 10.1126/scisignal.aaa4998. View

20.

Datta A, Loo S, Huang B, Wong L, Tan S, Tan T . SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget. 2014; 5(15):5920-33. PMC: 4171602. DOI: 10.18632/oncotarget.1874. View